Grossmann Liron D, Chen Chia-Hui, Uzun Yasin, Thadi Anusha, Wolpaw Adam J, Louault Kevin, Goldstein Yael, Surrey Lea F, Martinez Daniel, Calafatti Matteo, Gerelus Mark, Gao Peng, Lee Lobin, Patel Khushbu, Kaufman Rebecca S, Shani Guy, Farrel Alvin, Moshitch-Moshkovitz Sharon, Grimaldi Paris, Shapiro Matthew, Kendsersky Nathan M, Lindsay Jarrett M, Casey Colleen E, Krytska Kateryna, Scolaro Laura, Tsang Matthew, Groff David, Matkar Smita, Kalna Josh R, Mycek Emily, McDevitt Jayne, Runbeck Erin, Patel Tasleema, Bernt Kathrin M, Asgharzadeh Shahab, DeClerck Yves A, Mossé Yael P, Tan Kai, Maris John M
Division of Oncology and Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.
Division of Hematology-Oncology, Edmond and Lily Safra Children's Hospital, Sheba Medical Center, Tel-Hashomer, Israel.
Cancer Discov. 2024 Dec 2;14(12):2387-2406. doi: 10.1158/2159-8290.CD-24-0046.
Relapse rates in high-risk neuroblastoma remain exceedingly high. The malignant cells that are responsible for relapse have not been identified, and mechanisms of therapy resistance remain poorly understood. In this study, we used single-nucleus RNA sequencing and bulk whole-genome sequencing to identify and characterize the residual malignant persister cells that survive chemotherapy from a cohort of 20 matched diagnosis and definitive surgery tumor samples from patients treated with high-risk neuroblastoma induction chemotherapy. We show that persister cells share common mechanisms of chemotherapy escape, including suppression of MYC(N) activity and activation of NFκB signaling, and the latter is further enhanced by cell-cell communication between the malignant cells and the tumor microenvironment. Overall, our work dissects the transcriptional landscape of cellular persistence in high-risk neuroblastoma and paves the way to the development of new therapeutic strategies to prevent disease relapse. Significance: Approximately 50% of patients with high-risk neuroblastoma die of relapsed refractory disease. We identified the malignant cells that likely contribute to relapse and discovered key signaling pathways that mediate cellular persistence. Inhibition of these pathways and their downstream effectors is postulated to eliminate persister cells and prevent relapse. See related commentary by Wolf et al., p. 2308.
高危神经母细胞瘤的复发率仍然极高。导致复发的恶性细胞尚未被识别,治疗耐药机制也仍未得到充分理解。在本研究中,我们使用单核RNA测序和全基因组测序,从20例接受高危神经母细胞瘤诱导化疗的患者的配对诊断和根治性手术肿瘤样本队列中,识别并表征在化疗后存活的残留恶性持久性细胞。我们发现,持久性细胞具有共同的化疗逃逸机制,包括抑制MYC(N)活性和激活NFκB信号通路,而后者在恶性细胞与肿瘤微环境之间的细胞间通讯作用下进一步增强。总体而言,我们的工作剖析了高危神经母细胞瘤细胞持久性的转录图谱,为开发预防疾病复发的新治疗策略铺平了道路。意义:约50%的高危神经母细胞瘤患者死于复发难治性疾病。我们识别出了可能导致复发的恶性细胞,并发现了介导细胞持久性的关键信号通路。推测抑制这些通路及其下游效应器可消除持久性细胞并预防复发。见Wolf等人的相关评论,第2308页。